The US House of Representatives has approved legislation that would establish national standards for monitoring the distribution of prescription drugs and require drugs to be tracked through the distribution system. The House bill, HR 1919, would impose new requirements on companies that manufacture, handle, distribute and dispense drug products. The national system would mean that manufacturers, distributors and pharmacies would "track and track" drugs through the supply chain and, according to Republican Bob Latta, "protect against the threat posed by counterfeit drugs" (Bloomberg).
However, some say that HR 1919 doesn't go far enough, and are pushing for the Senate version, S957, which aims to transition the current lot-level tracing system to a unit-level system over the next 10 years.
What do you think? Which bill is the most likely to be implemented? Join our discussion on LinkedIn, or leave a comment below. Want more from Total BioPharma? Sign up to our newsletter – it doesn't cost anything and only takes a minute.
If you want to know more about compliance best practice for the pharma and medical devices industry, you might be interested in attending Pharma Compliance Europe 2013, 24-26 September 2013, London.